Biokinetic model for the calculation of dose coefficients for oral and intravenous administration of 14C labeled drugs

被引:0
|
作者
Krins, A. [1 ]
Fidorra, J. [2 ]
Pleiss, U. [3 ]
Sahre, P. [1 ]
Schoenmuth, T. [1 ]
机构
[1] VKTA Verein Kernverfahrenstech & Analyt Rossendor, Nucl Engn & Analyt Rossendorf Inc, Postfach 51 01 19, D-01314 Dresden, Germany
[2] Bayer AG, Radiat Protect, D-51368 Leverkusen, Germany
[3] Bayer AG, Pharma Prod Dev, D-42096 Wuppertal, Germany
关键词
D O I
暂无
中图分类号
TL [原子能技术]; O571 [原子核物理学];
学科分类号
0827 ; 082701 ;
摘要
A first order biokinetic model is presented for the calculation of dose coefficients from human activity excretion data after intravenous and oral administration of C-14 labeled drugs It is intended for the dose estimation in human studies in drug research, where the number of measurements is low and their uncertainty rather high. The model depends on only 6 parameters that are to be adjusted with the help of the measurement data. A comparison of measured and calculated activities in excreta of four human studies on C-14 labeled drugs revealed considerable agreement, although some limitations have to be accepted. In contrast to the biokinetic model for C-14 in organic compounds recommended by the International Commission on Radiological Protection (ICRP) the present model does not assume a fixed biological half-life of 40 days, but follows the experimental data. In consequence, the resulting dose coefficients differ from the ICRP value. For experimental data tested and assuming uniform activity distribution, the committed effective doses amount between one twenty-fifth to one fiftieth of the values calculated from the ICRP model. The uncertainty of the derived dose coefficients is estimated to be about +/- 50 %.
引用
收藏
页码:205 / 213
页数:9
相关论文
共 50 条
  • [21] Amisulpride: Metabolic and pharmacokinetic profile after 14C oral administration
    Canal, M
    Fraisse, J
    Thenot, JP
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S319 - S319
  • [22] Disposition of arsenobetaine in two marine fish species following administration of a single oral dose of [14C]arsenobetaine
    Amlund, Heidi
    Ingebrigtsen, Kristian
    Hylland, Ketil
    Ruus, Anders
    Eriksen, Dag Oistein
    Berntssen, Marc H. G.
    COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY, 2006, 143 (02): : 171 - 178
  • [23] Biokinetics of 13C in the human body after oral administration of 13C-labeled glucose as an index for the biokinetics of 14C
    Masuda, Tsuyoshi
    Tako, Yasuhiro
    Matsushita, Kensaku
    Takeda, Hiroshi
    Endo, Masahiro
    Nakamura, Yuji
    Hisamatsu, Shun'ichi
    JOURNAL OF RADIOLOGICAL PROTECTION, 2016, 36 (03) : 532 - 546
  • [24] Distribution of total 14C residue in egg yolk, albumen, and tissues following oral [14C]sulfamethazine administration to hens
    Shaikh, B
    Chu, PS
    JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2000, 48 (12) : 6404 - 6408
  • [25] Absorption, metabolism, distribution, and excretion of fimasartan ([14C]BR-A-657) following oral or intravenous administration to rats
    Lee, Joo-Han
    Chi, Yong-Ha
    Yoo, Byoung-Wook
    Kim, Ji-Han
    Tan, Hyun-Kwang
    Kim, Sang-Lin
    Bashir, Mohammad
    DRUG METABOLISM REVIEWS, 2006, 38 : 154 - 155
  • [26] Dose-linearity of the pharmacokinetics of an intravenous [14C]midazolam microdose in children
    van Groen, Bianca D.
    Vaes, Wouter H.
    Park, B. Kevin
    Krekels, Elke H. J.
    van Duijn, Esther
    Korgvee, Lenne-Triin
    Maruszak, Wioleta
    Grynkiewicz, Grzegorz
    Garner, R. Colin
    Knibbe, Catherijne A. J.
    Tibboel, Dick
    de Wildt, Saskia N.
    Turner, Mark A.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (10) : 2332 - 2340
  • [27] Pharmacokinetics, Disposition, and Biotransformation of [14C]Omecamtiv Mecarbil in Healthy Male Subjects after a Single Intravenous or Oral Dose
    Trivedi, Ashit
    Wahlstrom, Jan
    Mackowski, Mia
    Dutta, Sandeep
    Lee, Edward
    DRUG METABOLISM AND DISPOSITION, 2021, 49 (08) : 619 - 628
  • [28] The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [14C]-BI 425809 in Healthy Males
    Burkard, Ute
    Desch, Michael
    Shatillo, Yury
    Wunderlich, Glen
    Mack, Salome Rebecca
    Schlecker, Christina
    Teitelbaum, Aaron M.
    Liu, Pingrong
    Chan, Tom S.
    CLINICAL DRUG INVESTIGATION, 2022, 42 (01) : 87 - 99
  • [29] The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [14C]-BI 425809 in Healthy Males
    Ute Burkard
    Michael Desch
    Yury Shatillo
    Glen Wunderlich
    Salome Rebecca Mack
    Christina Schlecker
    Aaron M. Teitelbaum
    Pingrong Liu
    Tom S. Chan
    Clinical Drug Investigation, 2022, 42 : 87 - 99
  • [30] Distribution of total 14c residue in egg yolk, white, and tissues following oral 14C sulfamethazine administration to hens.
    Shaikh, B
    Paulson, GD
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1999, 218 : U69 - U70